GET 发表于 2025-3-25 06:10:34
Neutrino Physics and Astrophysics Val-Cit sequence is currently the most common choice for an enzymatic cleavable linker, novel approaches for releasing payloads, such as light stimulation and chemical reaction, have been reported. In this chapter, advances in development of linker technology will be reviewed.lethargy 发表于 2025-3-25 10:13:49
Lothar Oberauer,Judith Oberauergree of cancer stroma formation. This section focuses primarily on antibody-based nuclear medicine imaging targeting cancer stroma because it has the highest sensitivity and quantitative ability among the noninvasive imaging techniques applicable to clinical practice, and CAST therapy has been based on antibody-drug conjugates.FELON 发表于 2025-3-25 12:52:33
http://reply.papertrans.cn/23/2211/221092/221092_23.pngLUMEN 发表于 2025-3-25 18:23:39
CAST Diagnostic Imaginggree of cancer stroma formation. This section focuses primarily on antibody-based nuclear medicine imaging targeting cancer stroma because it has the highest sensitivity and quantitative ability among the noninvasive imaging techniques applicable to clinical practice, and CAST therapy has been based on antibody-drug conjugates.GAVEL 发表于 2025-3-25 21:04:48
http://reply.papertrans.cn/23/2211/221092/221092_25.pngcatagen 发表于 2025-3-26 01:29:07
http://reply.papertrans.cn/23/2211/221092/221092_26.pngFLOUR 发表于 2025-3-26 05:36:15
http://reply.papertrans.cn/23/2211/221092/221092_27.pngHormones 发表于 2025-3-26 12:32:07
http://reply.papertrans.cn/23/2211/221092/221092_28.pngAlcove 发表于 2025-3-26 14:49:22
ADCs on the Market and in Clinical Development of payload DNA topoisomerase I inhibitor is emerging. This review will focus on introduction of the four approved ADC drugs and promising novel ADCs with DNA topoisomerase I inhibitors, Sacituzumab Govitecan and Trastuzumab Deruxtecan, in late stages of clinical development.不法行为 发表于 2025-3-26 18:01:02
Polymeric Micelles the efficacy and reducing the side effects of anticancer agents. Indeed, several micellar formulations of anticancer agents have progressed to clinical trials. This article outlines polymer micelle from the viewpoint of formulation and particle design.